SCHEMBL20063045

SCHEMBL20063045

CCCn1c(NC(=O)c2cccc(C(C)=O)c2)nc2ccccc21

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 1/20 0.83
KDM4E B2RXH2 9/20 0.78
KMT2A Q03164 6/20 0.78
MEN1 O00255 5/20 0.78
TSHR P16473 4/20 0.78
OPRK1 P41145 3/20 0.76
HTT P42858 5/20 0.70
HSD17B10 Q99714 3/20 0.70
HPGD P15428 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
NPSR1 Q6W5P4 4/20 0.69
ALDH1A1 P00352 4/20 0.69
USP2 O75604 2/20 0.69
RXFP1 Q9HBX9 1/20 0.69
PPARG P37231 1/20 0.69
NCOA2 Q15596 1/20 0.69
NCOA1 Q15788 1/20 0.69
NCOA3 Q9Y6Q9 1/20 0.69
IRAK4 Q9NWZ3 5/20 0.69
LMNA P02545 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26325256 0.91 MAP3K7 (0.80) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL20063046 0.91 MAP3K7 (1.00) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL29722841 0.91 MAP3K7 (1.00) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL29850001 0.91 MAP3K7 (0.83) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL3812270 0.88 KDM4E (0.77) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL26325416 0.88 MAP3K7 (0.86) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL3798611 0.88 MAP3K7 (0.82) MAP3K7KDM4EKMT2AMEN1TSHR
Hydrochloric Acid SCHEMBL3791352 0.87 MAP3K7 (0.80) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL29827291 0.84 IRAK4 (0.89) MAP3K7KDM4EKMT2AMEN1TSHR
SCHEMBL25956620 0.84 IRAK4 (0.89) MAP3K7KDM4EKMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767298-B2 Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase DUKE UNIVERSITY (US) 2023-09-26 US disclosed
US-20180105500-A1 NOVEL INHIBITORS OF TRANSFORMING GROWTH FACTOR KINASE AND METHODS OF USE THEREOF DUKE UNIVERSITY 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105500-A1 NOVEL INHIBITORS OF TRANSFORMING GROWTH FACTOR KINASE AND METHODS OF USE THEREOF TAB1, BMP2K, SMAD3 MAP3K7 14/4885KDM4E 1526/4885KMT2A 2322/4885
US-11767298-B2 Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase TAB1, CHUK, TGFBR1 MAP3K7 19/4885KDM4E 915/4885KMT2A 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.